In VitroResistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In VitroResistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 59, Issue 1, Pages 590-598
Publisher
American Society for Microbiology
Online
2014-11-11
DOI
10.1128/aac.04201-14
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine
- (2014) Gaston R Picchio et al. ANTIVIRAL THERAPY
- Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine
- (2013) Hong-Tao Xu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroCharacterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
- (2013) Ming-Tain Lai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data
- (2012) Dushyantha Jayaweera et al. EXPERT OPINION ON PHARMACOTHERAPY
- Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine
- (2011) Stefano Alcaro et al. ChemMedChem
- Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies
- (2011) Laurence Rimsky et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations
- (2011) H.-T. Xu et al. JOURNAL OF VIROLOGY
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
- (2011) Calvin J Cohen et al. LANCET
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
- (2011) Jean-Michel Molina et al. LANCET
- Distinct Mutation Pathways of Non-Subtype B HIV-1 during In Vitro Resistance Selection with Nonnucleoside Reverse Transcriptase Inhibitors
- (2010) M.-T. Lai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine
- (2010) H. Gatanaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of the susceptibility of mutant HIV-1 to antiviral agents
- (2010) Ying-Jie Wang et al. JOURNAL OF VIROLOGICAL METHODS
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)
- (2009) Marie-Pierre de Béthune ANTIVIRAL RESEARCH
- Efavirenz: a decade of clinical experience in the treatment of HIV
- (2009) F. Maggiolo JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo
- (2008) Javier Martinez-Picado et al. VIRUS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started